Eyewire Today http://eyewiretoday.com/ Eyewire Today en-us Tue, 17 Oct 2017 14:55:50 GMT Tue, 17 Oct 2017 14:55:50 GMT EyewireToday.com Once-Daily Lyrica Formulation Wins FDA Approval http://eyewiretoday.com/view.asp?url=once-daily-lyrica-formulation-wins-fda-approval The FDA has approved Lyrica CR (pregabalin, Pfizer) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). The... Thu, 12 Oct 2017 04:00:00 GMT Investigational Low-Dose Fenfluramine Shows Promise in Phase 3 Trial for Dravet Syndrome http://eyewiretoday.com/view.asp?url=investigational-low-dose-fenfluramine-shows-promise-in-phase-3-trial Phase 3 findings suggest that the investigational ZX008 (low-dose fenfluramine hydrochloride, Zogenix) is effective for the treatment of Dravet syndrome. The study enrolled 119 patients across sites in the US, Canada, Europe, and Australia with a med... Fri, 29 Sep 2017 04:00:00 GMT Vitamin D Levels Tied to Risk of MS http://eyewiretoday.com/view.asp?url=vitamin-d-levels-tied-to-risk-of-ms Examining vitamin D levels in the blood may help predict whether a person is at risk of developing multiple sclerosis (MS), according to a large new study published Neurology (September 13). Using a repository of blood samples from more than 800,000 ... Thu, 14 Sep 2017 04:00:00 GMT Blood Test Shown to Accurately Identify Alzheimer’s Disease http://eyewiretoday.com/view.asp?url=blood-test-shown-to-accurately-identify-alzheimers-disease- A blood test may help identify and diagnose Alzheimer’s disease. In a study published in Proceedings of the National Academy of Sciences of the United States of America, researchers used attenuated total reflection FTIR (ATR-FTIR) spectroscopy ... Mon, 11 Sep 2017 04:00:00 GMT Project ALS and Amylyx Team Up to Test Phase 2 Compound http://eyewiretoday.com/view.asp?url=project-als-and-amylyx-team-up-to-test-phase-2-compound Project ALS and Amylyx Pharmaceuticals are collaborating to undertake pre-clinical studies to advance the understanding of Amylyx's oral compound AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). The studies will be conducted at t... Thu, 7 Sep 2017 04:00:00 GMT CLARITY Extension: Annual Short-Course Therapy with Investigational Oral Agent Effective in Relapsing MS http://eyewiretoday.com/view.asp?url=annual-short-course-therapy-with-investigational-oral-agent-effective-in-relapsing-ms New results suggest that patients with relapsing multiple sclerosis (MS) treated with two annual short courses of the investigational cladribine tablets (EMD Serono) may have similar clinical benefits to those seen with four years of treatment with c... Tue, 5 Sep 2017 04:00:00 GMT Study: Women and Men with APOE Epsilon 4 Gene at Equal Risk for Alzheimer’s Disease http://eyewiretoday.com/view.asp?url=study-women-and-men-with-apoe-epsilon-4-genes-at-equal-risk-for-alzheimers-disease Although women with the APOE e3/e4 genotype have been thought to be at greater risk for Alzheimer’s disease, new research suggests that men and women between 55 and 85 years of age with the genotype have nearly the same odds of developing the d... Thu, 31 Aug 2017 04:00:00 GMT AstraZeneca and Takeda Strike $400 Million Development Deal for Investigational Parkinson’s Agent http://eyewiretoday.com/view.asp?url=astrazeneca-and-takeda-ink-400-million-development-deal-for-investigational-parkinsons-agent AstraZeneca and Takeda Pharmaceutical Company Limited will jointly develop and commercialize an investigational alpha-synuclein antibody currently in development for the treatment of Parkinson’s disease (PD) known as MEDI1341. Differentiated by... Tue, 29 Aug 2017 04:00:00 GMT Gut Bacteria May Play Preventive Role in MS http://eyewiretoday.com/view.asp?url=gut-bacteria-may-play-preventive-role-in-ms New findings support the increasingly prominent hypothesis that gut bacteria play a role in autoimmune diseases such as multiple sclerosis (MS). Specifically, a study published in Cell Reports (Aug;20(6):1269-1277) shows that a bacteria present in th... Tue, 15 Aug 2017 04:00:00 GMT Stroke Rates Decreasing Among Men, Steady in Women http://eyewiretoday.com/view.asp?url=stroke-rates-decreasing-among-men-steady-in-women- Although stroke incidence rates are dropping overall, new findings suggest that those decreases are only seen in men. In a new study published in Neurology (published online August 9), investigators tracked all incident strokes among a population of ... Thu, 10 Aug 2017 04:00:00 GMT AAIC 2017: Healthy Diets Tied to Decreased Likelihood of Cognitive Impairment In Older Individuals http://eyewiretoday.com/view.asp?url=aaic-2017-healthy-diets-tied-to-decreased-likelihood-of-cognitive-impairment-in-older-individuals The benefits of a healthy diet may extend to cognitive health, according to findings presented at the Alzheimer’s Association International Conference in London. Among nearly 6,000 older adults in the Health and Retirement study, investigators ... Mon, 17 Jul 2017 04:00:00 GMT Visual System Changes May Represent an Early Signal of Parkinson’s Disease http://eyewiretoday.com/view.asp?url=visual-system-changes-may-represent-an-early-signal-of-parkinsons-disease Changes in the intracranial visual system may be a signal of Parkinson’s disease (PD), according to new findings published in Radiology. Using MRI, researchers evaluated 21 patients with newly diagnosed PD and 20 age-matched controls to assess ... Wed, 12 Jul 2017 04:00:00 GMT Sleep Disturbances Linked to Alzheimer’s Disease http://eyewiretoday.com/view.asp?url=sleep-disturbances-linked-to-alzheimers-disease- Poor sleep may be a sign that otherwise healthy individuals may have an increased risk of developing Alzheimer’s disease later in life over those who do not have sleep problems, according to a study published in the July 5, 2017 edition of Neur... Thu, 6 Jul 2017 04:00:00 GMT Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment http://eyewiretoday.com/view.asp?url=phase-3-results-published-for-investigational-levodopa-induced-dyskinesia-treatment Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD... Wed, 14 Jun 2017 04:00:00 GMT AHS 2017: Amgen’s CGRP Inhibitor Reduces Migraine Days http://eyewiretoday.com/view.asp?url=amgen-unveils-positive-phase-2-data-for-cgrp-inhibitor New Phase 2 data show that Amgen’s investigational investigational CGRP inhibitor erenumab is effective at preventing migraine in patients experiencing 15 or more migraine days per month. In a study presented at the recent American Headache Soc... Tue, 13 Jun 2017 04:00:00 GMT Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT http://eyewiretoday.com/view.asp?url=anti-alpha-synuclein-antibody-shows-early-potential-as-parkinsons-dmt PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), according to a study presented at the recent International Congress of Parkinso... Fri, 9 Jun 2017 04:00:00 GMT AHS 2017 Meeting: Non-Invasive Medical Devices Show Promise for Severe Headaches http://eyewiretoday.com/view.asp?url=ahs-2017-meeting-non-invasive-medical-devices-show-promise-for-severe-headaches Results from studies presented at the American Headache Society Annual Meeting in Boston suggest that non-invasive medical devices offer effective interventions for individuals with migraine.New findings from a randomized, placebo-controlled study sh... Thu, 8 Jun 2017 04:00:00 GMT AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine http://eyewiretoday.com/view.asp?url=ahs-2017-meeting-prochlorperazine-more-effective-than-the-opioid-hydromorphone-for-acute-migraine A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazine is more effective than the opioid drug, hydromor... Thu, 8 Jun 2017 04:00:00 GMT Smartphone Sensor Data Offer Insights Into Daily Functioning in Patients with Parkinson’s Disease http://eyewiretoday.com/view.asp?url=smartphone-sensor-data-offer-insights-into-daily-functioning-in-patients-with-parkinsons-disease Smartphones are a valuable resource in gaining mobility data in patients with Parkinson’s disease, according to new research presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders (Abstract 541). Evalua... Wed, 7 Jun 2017 04:00:00 GMT Teva’s Fremanezumab Reduces Monthly Headache Days in Phase 3 Chronic Migraine Study http://eyewiretoday.com/view.asp?url=tevas-fremanezumab-reduces-monthly-headache-days-in-phase-3-chronic-migraine-study Results from the Phase 3 HALO study suggest that fremanezumab (Teva Pharmaceuticals) reduces the number of monthly headache days in patients with chronic migraine. Fremanezumab is a fully-humanized monoclonal antibody targeting the CGRP ligand. In t... Thu, 1 Jun 2017 04:00:00 GMT Neurodegenerative Diseases Linked by Abnormal Proteins Causing Similar Damage to Brain Cells http://eyewiretoday.com/view.asp?url=neurodegenerative-diseases-linked-by-abnormal-proteins-causing-similar-damage-to-brain-cells Abnormal proteins found in Alzheimer's disease, Parkinson's disease, and Huntington's disease share a similar ability to cause damage when they invade brain cells, according to recently published findings (Acta Neuropathol, May 19, 2017).... Tue, 30 May 2017 04:00:00 GMT NEJM Publishes Phase 3 Data for Epidiolex in Dravet Syndrome as Manufacturer Eyes Mid-2017 NDA Submission http://eyewiretoday.com/view.asp?url=nejm-publishes-phase-3-data-for-epidiolex-in-dravet-syndrome-as-manufacturer-eyes-mid-2017-nda-submission The New England Journal of Medicine has published results from a Phase 3 study showing that Epidiolex (cannabidiol, GW Pharmaceuticals) reduces monthly convulsive seizure frequency compared to placebo in children with Dravet syndrome. The study rando... Fri, 26 May 2017 04:00:00 GMT Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial http://eyewiretoday.com/view.asp?url=celgenes-investigational-ms-agent-reduces-annual-relapse-rate-but-falls-short-of-disability-endpoint-in-phase-3-trial New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way but does not significantly impact disease disability. In the RADIANCE tria... Tue, 23 May 2017 04:00:00 GMT Migraine Prevalence Higher in Collegiate Athletes, New Study Finds http://eyewiretoday.com/view.asp?url=migraine-prevalence-higher-in-collegiate-athletes-new-study-finds New findings suggest that collegiate athletes have an increased prevalence of migraines, with female athletes being particularly affected. In a retrospective cross-section survey, researchers evaluated 834 student athletes from NCAA Division-I instit... Fri, 19 May 2017 04:00:00 GMT Lilly’s Investigational Monoclonal Antibody for Migraine Scores Positive Phase 3 Results http://eyewiretoday.com/view.asp?url=lillys-investigational-monoclonal-antibody-for-migraine-scores-positive-phase-3-results New Phase 3 data suggest that Eli Lilly’s investigational monoclonal antibody galcanezumab may significantly reduce the number of monthly migraine headache days. In the EVOLVE-1 study, patients with episodic migraine treated with galcanezumab 1... Fri, 12 May 2017 04:00:00 GMT